COMPOSITIONS COMPRISING BACTERIAL STRAINS

• US 20180369293A1
• Filed: 06/28/2018
• Published: 12/27/2018
• Est. Priority Date: 12/12/2016
• Status: Active Grant

• Current Assignee: Armistice Capital Master Fund Ltd. (Armistice Capital LLC)
• Original Assignee: 4D Pharma PLC
• Inventors: Jeffery, Ian, Shanahan, Fergus, O'toole, Paul, Stevenson, Alex, Mulder, Imke, Savignac, Helene
• Granted Patent: US 10,485,830 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2035/11 Medicinal preparations comprising living procariotic cells
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61K 9/48 Preparations in capsules, e.g. of gelatin, of chocolate A61K9/0004 takes precedence; bite capsules A61K9/0056
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Provided are compositions comprising a bacterial strain of the genus Blautia, for use in a method of increasing the microbiota diversity and/or inducing stability of the microbiota of a subject.

Claims

1. A composition comprising a bacterial strain of the genus Blautia, for use in a method of increasing the microbiota diversity and/or inducing stability of the microbiota of a subject.

2. The composition according to claim 1, for use in a method of treating or preventing a disease or disorder in a subject, wherein the disease or disorder is associated with a level of microbiota diversity that is reduced relative to the microbiota diversity of a healthy subject, and wherein the treatment or prevention comprises increasing the microbiota diversity in the subject.

3. The composition according to claim 2, wherein the subject has a reduced microbiota diversity relative to a healthy subject.

5. The composition according to claim 1, for use in a method of treating or preventing a disease or disorder in a subject, wherein the disease or disorder is associated with reduced stability of the microbiota compared to a healthy subject, and wherein the treatment or prevention comprises inducing stability of the microbiota in the subject.

6. The composition according to claim 2, wherein the subject has reduced stability of its microbiota compared to a healthy subject.

7. The composition of claim 1, wherein the composition is for use in a method of treatment or prevention of IBS, IBD, obesity, type 2 diabetes, one or more infectious diseases, one or more allergic diseases, one or more autoimmune diseases or one or more metabolic diseases/disorders.

9. The composition of claim 1, wherein the increase in microbiota diversity and/or induction of stability of microbiota is for both acetogenic and non-acetogenic bacteria.

23. The composition of claim 1, wherein the bacterial strain is of Blautia hydrogenotrophica.

24. The composition of claim 1, wherein the composition comprises a bacterial strain of the species Blautia hydrogenotrophica, for use in a method of increasing the microbiota diversity and/or inducing the stability of the microbiota in a subject diagnosed with IBS.

25. The composition of claim 1, wherein the bacterial strain has a 16s rRNA sequence that is at least 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of Blautia hydrogenotrophica.

26. The composition of claim 1, wherein the bacteria strain is the Blautia hydrogenotrophica bacterium deposited under accession number DSM 10507 and also under accession number DSM 14294.

27. The composition of claim 1, wherein the composition is for oral administration.

28. The composition of claim 1, wherein the composition comprises one or more pharmaceutically acceptable excipients or carriers.

29. The composition of claim 1, wherein the bacterial strain is lyophilised.

30. The composition of claim 1, wherein the bacterial strain is viable.

31. The composition of claim 1, wherein the bacterial strain is capable of partially or totally colonising the intestine.

32. The composition of claim 1, which comprises a single strain of Blautia.

4. (canceled)

8. (canceled)

10. A composition comprising a bacterial strain of the genus Blautia, for use in a method of treatment or prevention of IBS, IBD, obesity, type 2 diabetes, one or more infectious diseases, one or more allergic diseases, one or more autoimmune diseases or one or more metabolic diseases/disorders.

11-22. -22. (canceled)

33-37. -37. (canceled)

38. A method of increasing or maintaining the intestinal microbiota diversity in a subject and/or inducing stability of the intestinal microbiota in a subject, comprising administering a composition comprising a bacterial strain of the genus Blautia to a subject in need thereof.

39. A method according to claim 38, wherein the Blautia is Blautia hydrogenotrophica.

40. (canceled)